GLP1R and obesity due to melanocortin 4 receptor deficiency: Supporting this broader neuropsychiatric impact, the findings of Pierret et al’s review and meta-analysis indicate that treatment with GLP-1 receptor agonists in obesity/overweight is linked to enhanced mental well-being and quality of life, along with established benefits for physical health [45].